{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:50:57Z","timestamp":1770450657242,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["GR524525"],"award-info":[{"award-number":["GR524525"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.det.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T20:30:31Z","timestamp":1494102631000},"page":"335-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Long-Term Treatment of Atopic Dermatitis"],"prefix":"10.1016","volume":"35","author":[{"given":"James C.","family":"Prezzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2017.02.007_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.det.2017.02.007_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12887-016-0607-9","article-title":"Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis","volume":"16","author":"Siegfried","year":"2016","journal-title":"BMC Pediatr"},{"issue":"5","key":"10.1016\/j.det.2017.02.007_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaad.2016.05.043","article-title":"Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review","volume":"75","author":"Barbarot","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/jid.2014.320","article-title":"The harmonizing outcome measures for eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology","volume":"135","author":"Schmitt","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4370","article-title":"Systematic review of treatments for atopic eczema","volume":"4","author":"Hoare","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.det.2017.02.007_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib8","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1542\/peds.2008-2217","article-title":"Treatment of staphylococcus aureus colonization in atopic dermatitis decreases disease severity","volume":"123","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.det.2017.02.007_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2340\/00015555-2051","article-title":"Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial","volume":"95","author":"Akerstrom","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2017.02.007_bib10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.326.7403.1367","article-title":"Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study","volume":"326","author":"Berth-Jones","year":"2003","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.det.2017.02.007_bib11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/1346-8138.13408","article-title":"Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study","volume":"43","author":"Fukuie","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-3038.2008.00735.x","article-title":"Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?","volume":"20","author":"Glazenburg","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.det.2017.02.007_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2133.2002.05006.x","article-title":"Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients","volume":"147","author":"Hanifin","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546630310013388","article-title":"Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream","volume":"14","author":"Kirkup","year":"2003","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2017.02.007_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630410033781","article-title":"Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis","volume":"15","author":"Luger","year":"2004","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2017.02.007_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2340\/00015555-0803","article-title":"One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial","volume":"90","author":"Mandelin","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2017.02.007_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2133.2008.08436.x","article-title":"Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study","volume":"158","author":"Peserico","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib18","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2133.2005.06592.x","article-title":"A\u00a0multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis","volume":"152","author":"Reitamo","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1542\/peds.2014-1990","article-title":"Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial","volume":"135","author":"Sigurgeirsson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.det.2017.02.007_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2008.08484.x","article-title":"Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial","volume":"158","author":"Gollnick","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib21","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1067\/mjd.2001.109810","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy","volume":"44","author":"Hanifin","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib22","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1067\/mjd.2001.109817","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety","volume":"44","author":"Soter","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000078462","article-title":"Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis","volume":"208","author":"Meurer","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2017.02.007_bib24","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1365-2133.2008.08813.x","article-title":"Proactive disease management with 0\u00b703% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study","volume":"159","author":"Tha\u00e7i","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1398-9995.2008.01683.x","article-title":"Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment","volume":"63","author":"Wollenberg","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.det.2017.02.007_bib26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/j.1468-3083.2009.03303.x","article-title":"Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial","volume":"23","author":"Wir\u00e9n","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2017.02.007_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2147\/CCID.S87987","article-title":"Management of atopic dermatitis: safety and efficacy of phototherapy","volume":"8","author":"Patrizi","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/000155501750208137","article-title":"Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis","volume":"81","author":"Granlund","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2017.02.007_bib29","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(00)05114-X","article-title":"Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial","volume":"357","author":"Reynolds","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.det.2017.02.007_bib30","first-page":"139","article-title":"High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis","volume":"4","author":"Bemanian","year":"2005","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.det.2017.02.007_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt","volume":"172","author":"El-Khalawany","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.det.2017.02.007_bib32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib34","first-page":"33","article-title":"Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross-over study comparing two efficient treatment modalities","volume":"1","author":"Koppelhus","year":"2014","journal-title":"Front Med (Lausanne)"},{"issue":"135 Suppl","key":"10.1016\/j.det.2017.02.007_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2133.1996.tb00704.x","article-title":"The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens","volume":"48","author":"Zonneveld","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A\u00a0randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.det.2017.02.007_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.det.2017.02.007_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2133.1997.tb02136.x","article-title":"Renal biopsy findings in long-term cyclosporin treatment of psoriasis","volume":"136","author":"Zachariae","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/rheumatology\/38.3.254","article-title":"Cyclosporin A therapy in rheumatoid arthritis: only strict application of the guidelines for safe use can prevent irreversible renal function loss","volume":"38","author":"van den Borne","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.det.2017.02.007_bib41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"24","key":"10.1016\/j.det.2017.02.007_bib42","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2017.02.007_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0190-9622(95)90014-4","article-title":"Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients","volume":"33","author":"Jorizzo","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.324.7340.768","article-title":"Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema","volume":"324","author":"Thomas","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.det.2017.02.007_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mai.2002.126500","article-title":"Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug","volume":"110","author":"Kapp","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.det.2017.02.007_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000065863","article-title":"Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study","volume":"205","author":"Meurer","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2017.02.007_bib47","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1067\/mjd.2001.109813","article-title":"A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients","volume":"44","author":"Paller","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib48","doi-asserted-by":"crossref","first-page":"e1210","DOI":"10.1542\/peds.2008-1343","article-title":"Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use","volume":"122","author":"Paller","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.det.2017.02.007_bib49","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2008.02.008","article-title":"Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle","volume":"58","author":"Breneman","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1525-1470.2009.00981.x","article-title":"Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis","volume":"26","author":"Ruer-Mulard","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.det.2017.02.007_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/09546630600647297","article-title":"Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis","volume":"17","author":"Siegfried","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.det.2017.02.007_bib52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1468-3083.2008.02785.x","article-title":"Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis","volume":"22","author":"Sigurgeirsson","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2017.02.007_bib53","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1468-3083.2010.03577.x","article-title":"Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months","volume":"24","author":"Thaci","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2017.02.007_bib54","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children","volume":"110","author":"Wahn","year":"2002","journal-title":"Pediatrics"}],"updated-by":[{"DOI":"10.1016\/j.det.2017.08.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000}}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863517300311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863517300311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T23:54:21Z","timestamp":1719186861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863517300311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0733863517300311"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2017.02.007","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.det.2017.08.001","asserted-by":"object"}]},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Treatment of Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}